The post STAT+: AbbVie Parkinson’s drug helps improve symptoms in late-stage study first appeared on USSA News | The Tea Party’s Front Page.. Visit USSANews.com.
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.
In the Phase 3 trial, early-stage Parkinson’s patients on the highest dose of the drug, called tavapadon, experienced a 10.2-point improvement on tests that measured motor symptoms and quality of life, also known as the MDS-UPDRS parts II and III. Meanwhile, those on placebo saw a 1.8-point worsening.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
The post STAT+: AbbVie Parkinson’s drug helps improve symptoms in late-stage study first appeared on USSA News | The Tea Party’s Front Page.. Visit USSANews.com.
About The Author
Discover more from MEK Enterprises Blog - Breaking News, SEO, Information, and Making Money Online!
Subscribe to get the latest posts sent to your email.
